AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
aficamten 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cardiac myosin inhibitors | 5800 | 2364554-48-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Aficamten is a reversible allosteric cardiac myosin inhibitor that binds directly to the motor domain of cardiac myosin and prevents it from entering the force-producing state. Nonclinical data indicate that aficamten is selective for the cardiac isoform of myosin compared to fast skeletal myosin. Specifically, aficamten inhibited bovine cardiac myofibrillar ATPase with approximately 5-fold higher potency than rabbit fast skeletal myofibrillar ATPase. It is designed to reduce the hypercontractility in the cardiac sarcomere fundamental to the pathophysiology of HCM. The consequent reduction in cardiac contractility reduces LVOT obstruction in HCM patients.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 12, 2026 | EMA | Cytokinetics (Ireland) Limited | |
| Dec. 19, 2025 | FDA | Cytokinetics |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Obstructive hypertrophic cardiomyopathy (HCM) | indication | 233873004 | DOID:11984 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 10MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | 10836755 | Jan. 18, 2039 | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS |
| 15MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | 10836755 | Jan. 18, 2039 | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS |
| 20MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | 10836755 | Jan. 18, 2039 | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS |
| 5MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | 10836755 | Jan. 18, 2039 | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS |
| 10MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | 12370179 | July 15, 2042 | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS |
| 15MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | 12370179 | July 15, 2042 | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS |
| 20MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | 12370179 | July 15, 2042 | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS |
| 5MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | 12370179 | July 15, 2042 | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 10MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | Dec. 19, 2030 | NEW CHEMICAL ENTITY |
| 15MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | Dec. 19, 2030 | NEW CHEMICAL ENTITY |
| 20MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | Dec. 19, 2030 | NEW CHEMICAL ENTITY |
| 5MG | MYQORZO | CYTOKINETICS | N219083 | Dec. 19, 2025 | RX | TABLET | ORAL | Dec. 19, 2030 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Myosin-7 | Enzyme | INHIBITOR | IC50 | 6 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| 6I6 | PDB_CHEM_ID |
| CHEMBL4847050 | ChEMBL_ID |
| C000731669 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4044505 | VANDF |
| C5555443 | UMLSCUI |
| CHEBI:747213 | CHEBI |
| 11544 | INN_ID |
| 139331495 | PUBCHEM_CID |
| 400089 | MMSL |
| 44598 | MMSL |
| d10355 | MMSL |
| 020315 | NDDF |
| 11524 | IUPHAR_LIGAND_ID |
| B1I77MH6K1 | UNII |
| 2731469 | RXNORM |
| D12253 | KEGG_DRUG |
Pharmaceutical products:
None